Pharmacytimes: Condition Center: Hepatitis C http://www.pharmacytimes.com/condition-resources/hepatitisc/condition-rss Hepatitis C en-us Fri, 02 Dec 2016 07:53:40 UTC Fri, 02 Dec 2016 07:53:40 UTC Declining Hepatitis C Sales http://www.pharmacytimes.com/contributor/jason-poquette/2016/11/declining-hepatitis-c-sales-failure-or-success Reports show that sales and revenue from Hepatitis C treatments are declining. What does this mean for patients? 10:28 PM, Wed November 16, 2016 Pharmacist Charged for Hepatitis C Drug Fraud http://www.pharmacytimes.com/news/pharmacist-charged-for-hepatitis-c-drug-fraud A former Clinical Pharmacy Manager at a Walgreens specialty pharmacy pleaded guilty to health care fraud crimes committed between October 2014 and April 2016. 8:00 AM, Thu October 27, 2016 5 Highlights from the Pharmacy World This Week http://www.pharmacytimes.com/contributor/charles-ng-pharmd-mba-candidate-2017/2016/10/5-highlights-from-the-pharmacy-world-this-week In case you missed it, here’s the hottest news in pharmacy this week: 11:13 PM, Thu October 6, 2016 Trouble on the Horizon for Gilead's HCV Market Hold http://www.pharmacytimes.com/contributor/austin-hewlett-pharmd-mba-candidate/2016/09/trouble-on-the-horizon-for-gileads-hcv-market-hold Gilead Sciences—maker of hepatitis C virus blockbusters Sovaldi, Harvoni, and, most recently, Epclusa—has come under increasing scrutiny for declining revenues, both in the near-term and beyond. 3:05 AM, Fri September 2, 2016 Managing Drug Interactions in HIV/HCV-Coinfected Patients http://www.pharmacytimes.com/contributor/timothy-o-shea/2016/08/managing-drug-interactions-in-hiv-hcv-coinfected-patients Patients taking mediations for both HIV and HCV must be closely monitored for drug-drug interactions. 3:19 AM, Tue August 23, 2016 Zepatier for Hep C: What Pharmacists Should Know http://www.pharmacytimes.com/contributor/timothy-o-shea/2016/08/zepatier-for-hep-c-what-pharmacists-should-know This fixed-dose combination of elbasvir and grazoprevir is indicated to treat chronic HCV genotypes 1 or 4 with or without ribavirin in adults. 10:38 PM, Sun August 14, 2016 FDA Approves Hep C Treatment for All Major Genotypes http://www.pharmacytimes.com/news/fda-approves-hep-c-treatment-for-all-major-genotypes The FDA today approved Gilead Sciences’ sofosbuvir and velpatasvir (Epclusa) for the treatment of adult patients with chronic hepatitis C virus both with and without cirrhosis. 4:25 AM, Tue June 28, 2016 New Indications Approved for Harvoni http://www.pharmacytimes.com/product-news/new-indications-approved-for-harvoni The FDA has approved Gilead Sciences’ supplemental new drug applications for ledipasvir/sofosbuvir (Harvoni), which can treat chronic hepatitis C patients with advanced liver disease. 7:00 AM, Fri February 19, 2016 Zepatier Approved as Hep C Treatment http://www.pharmacytimes.com/product-news/zepatier-approved-as-hep-c-treatment The FDA has approved Merck’s elbasvir and grazoprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotypes 1 and 4 infections. 7:00 AM, Tue February 2, 2016 HIV Coinfection Doesn't Affect Hep C Treatment Adherence http://www.pharmacytimes.com/resource-centers/hiv/hiv-coinfection-doesnt-affect-hep-c-treatment-adherence One-third of HIV-infected Americans are co-infected with hepatitis C virus (HCV), and 75% to 90% of HIV-positive intravenous drug users are co-infected. 11:59 PM, Wed January 20, 2016 Hep C Treatment for All Genotypes Granted Priority Review http://www.pharmacytimes.com/product-news/hep-c-treatment-for-all-genotypes-granted-priority-review The FDA has given priority review status to a new drug application for Gilead Sciences’ sofosbuvir and velpatasvir as a treatment for chronic genotype 1-6 hepatitis C virus infection. 9:00 PM, Tue January 5, 2016 Once-Daily Viekira Pak Under FDA Review http://www.pharmacytimes.com/product-news/once-daily-viekira-pak-under-fda-review The FDA is taking into consideration a once-daily formulation of AbbVie's ombitasvir, paritaprevir, and ritonavir tablets co-packaged with dasabuvir tablets (Viekira Pak). 7:00 AM, Wed December 9, 2015 Newly Infected HIV Patients Have Low Prevalence of Hep C Co-Infection http://www.pharmacytimes.com/resource-centers/hiv/newly-infected-hiv-patients-have-low-prevalence-of-hep-c-co-infection The World Health Organization indicates that 35 million individuals have HIV worldwide, and 4 to 5 million HIV-infected patients are co-infected with hepatitis C virus. 10:00 PM, Thu December 3, 2015 Merck's Hepatitis C Combination Candidate Receives Priority Review http://www.pharmacytimes.com/product-news/mercks-hepatitis-c-combination-candidate-receives-priority-review The FDA has granted priority review to Merck's chronic hepatitis C virus (HCV) treatment candidate grazoprevir/elbasvir. 10:00 PM, Fri July 31, 2015 Hepatitis C Combination Therapy Seeks Label Update http://www.pharmacytimes.com/product-news/hepatitis-c-combination-therapy-seeks-label-update Janssen is asking the FDA to update the label of its once-daily hepatitis C virus (HCV) drug simeprevir (Olysio). 1:51 AM, Mon July 27, 2015 Medicaid Violations Hinder Hepatitis C Drug Access http://www.pharmacytimes.com/news/medicaid-violations-hinder-hepatitis-c-drug-access Many states implement unlawful and life-threatening restrictions on Medicaid coverage for the hepatitis C virus drug, sofosbuvir. 4:00 AM, Sat July 4, 2015 Prescription Payment Caps Enacted in California http://www.pharmacytimes.com/news/Prescription-Payment-Caps-Enacted-in-California California's Affordable Care Act health insurance exchange marketplace is the first in the nation to enact a payment cap policy for expensive specialty drugs. 11:51 PM, Sun June 28, 2015 New Drugs Health-System Pharmacists Should Know http://www.pharmacytimes.com/news/new-drugs-health-system-pharmacists-should-know Here are new drugs for 2015 pharmacists can expect to handle. 12:26 AM, Thu June 18, 2015 Pharmacists Need to Weigh Cost-Benefit of Chronic Hepatitis C Drugs http://www.pharmacytimes.com/news/Pharmacists-Need-to-Weigh-CostBenefit-of-Chronic-Hepatitis-C-Drugs High costs associated with new chronic hepatitis C virus (HCV) treatments should prompt pharmacists to reconsider their formula for determining the drugs' worth. 11:30 PM, Sun June 14, 2015 Merck Drug Seeks FDA Approval for 3 Hepatitis C Genotypes http://www.pharmacytimes.com/product-news/Merck-Drug-Seeks-FDA-Approval-for-3-Hepatitis-C-Genotypes Merck is seeking FDA approval for its once-daily, single-tablet grazoprevir/elbasvir combination for the treatment of adult patients with chronic hepatitis C virus (HCV) genotypes 1, 4, or 6 infection. 1:38 AM, Mon June 1, 2015